Silverman S L
West Los Angeles VA Medical Center, UCLA 90073, USA.
Endocrine. 1997 Apr;6(2):199-202. doi: 10.1007/BF02738965.
Nasal calcitonin is a newly approved treatment for established osteoporosis that increases lumbar spine bone mass, is safe, and well tolerated. Fracture efficacy data is not yet available, although preliminary results are promising. The dose for established osteoporosis is 200 IU. The dose for prevention of postmenopausal osteoporosis has not been established. Nasal calcitonin may be analgesic to bone and may be of benefit in glucocorticoid-induced vertebral osteoporosis. Nasal spray calcitonin may be of benefit to the symptomatic patient with acute vertebral fracture, the complex patient, or the patient with established osteoporosis who is intolerant of bisphosphonates or estrogen.
鼻用降钙素是一种新批准用于治疗确诊骨质疏松症的药物，可增加腰椎骨量，安全性好且耐受性良好。尽管初步结果很有前景，但骨折疗效数据尚未可得。确诊骨质疏松症的剂量为200国际单位。预防绝经后骨质疏松症的剂量尚未确定。鼻用降钙素可能对骨骼有止痛作用，可能有益于糖皮质激素诱导的椎体骨质疏松症。鼻用喷雾降钙素可能对急性椎体骨折的有症状患者、情况复杂的患者或确诊骨质疏松症且不耐受双膦酸盐或雌激素的患者有益。
